Oak Grove Capital’s Amgen AMGN Stock Holding History

Oak Grove Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-128	Closed	-$22K	–	160
2018 Q1	$22K	Buy	+128	New	+$23.5K	0.02%	91

Other funds holding AMGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oak Grove Capital's AMGN Position: Q2 2018 in Review

Oak Grove Capital sold out of Amgen (AMGN) in Q2 2018, closing a stake of 128 shares — an estimated $22K sold.

Oak Grove Capital first reported a position in AMGN in Q1 2018 and held it in 1 quarter. The position peaked at $22K in Q1 2018. 1,763 funds tracked by Wall St. Rank hold AMGN as of Q2 2018.

Oak Grove Capital reported no remaining Amgen position as of Q2 2018 after selling out during the quarter.
Oak Grove Capital sold 128 Amgen shares in Q2 2018, an estimated $22K.
Oak Grove Capital first reported a position in Amgen in Q1 2018 and held it in 1 quarter.
Oak Grove Capital's Amgen position peaked at $22K in Q1 2018.
1,763 funds tracked by Wall St. Rank held Amgen as of Q2 2018.

Based on Oak Grove Capital's 13F filing for Q2 2018, filed 9 Nov 2018.